Zymeworks Inc.

ZYME Nasdaq CIK: 0001937653

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709
Mailing Address 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709
Phone 302-274-8744
Fiscal Year End 1231
EIN 883099146

Financial Overview

FY2025

$124.32M
Total Liabilities

Recent SEC Filings

Form Type Date Filed Document
3 Initial insider ownership report April 7, 2026 View on SEC
4 Insider stock transaction report April 7, 2026 View on SEC
8-K Current report of material events April 1, 2026 View on SEC
8-K Current report of material events March 2, 2026 View on SEC
8-K Current report of material events March 2, 2026 View on SEC
10-K Annual financial report March 2, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 13, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 12, 2026 View on SEC
3 Initial insider ownership report February 2, 2026 View on SEC
4 Insider stock transaction report January 13, 2026 View on SEC

Annual Reports

10-K March 2, 2026
  • Lead candidate zanidatamab advanced to late-stage clinical development with upcoming data readouts expected in late 2024/early 2025.
  • Strong strategic collaborations with major pharmaceutical companies (e.g., Jazz, J&J, GSK) provide non-dilutive funding and validate technology platforms.
View Analysis

Material Events

8-K Leadership Change April 1, 2026
Medium Impact
  • Appointment of Kristin Stafford as CFO signals transition to commercial-stage operations.
  • Separation of CEO and CFO roles reduces key-person risk and improves governance.
View Analysis

Insider Trading

STRONG SELL 4 insiders 10 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.